[ad_1]
Biocept Inc (NASDAQ: BIOC) CEO Mike Nall told Proactive Investors that the California-based molecular diagnostics company is making progress in its Artificial Intelligence collaboration with Prognos Inc.
Nall says that Prognos uses data generated by Biocept with its liquid biopsy badays of different cancers to badyze trends and identify and develop targeted therapies based on the genomic tumor of a patient. According to Nall, investors should investigate how Biocept and Prognos would sell this data to Big Pharma and create an additional revenue stream.
Source link
